Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH) + r-hFSH
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Reproductive Techniques, Assisted
Conditions
Reproductive Techniques, Assisted
Trial Timeline
Mar 1, 2005 → Apr 1, 2009
NCT ID
NCT01071200About Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH) + r-hFSH
Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH) + r-hFSH is a phase 3 stage product being developed by Merck for Reproductive Techniques, Assisted. The current trial status is terminated. This product is registered under clinical trial identifier NCT01071200. Target conditions include Reproductive Techniques, Assisted.
What happened to similar drugs?
0 of 1 similar drugs in Reproductive Techniques, Assisted were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01071200 | Phase 3 | Terminated |
Competing Products
2 competing products in Reproductive Techniques, Assisted
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Durvalumab + Tremelimumab | AstraZeneca | Phase 2 | 39 |
| Gonal-f® + Pergoveris® + Pergoveris® + Recombinant human chorionic gonadotropin (r-hCG) | Merck | Phase 3 | 40 |